Form 8-K - Current report:
SEC Accession No. 0001193125-24-196475
Filing Date
2024-08-08
Accepted
2024-08-08 07:20:53
Documents
16
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d857022d8k.htm   iXBRL 8-K 25481
2 EX-99.1 d857022dex991.htm EX-99.1 182202
6 GRAPHIC g857022dsp5.jpg GRAPHIC 11029
7 GRAPHIC g857022dsp5a.jpg GRAPHIC 1964
  Complete submission text file 0001193125-24-196475.txt   369551

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20240808.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20240808_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20240808_pre.xml EX-101.PRE 10815
19 EXTRACTED XBRL INSTANCE DOCUMENT d857022d8k_htm.xml XML 3557
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 241186045
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)